XML 46 R35.htm IDEA: XBRL DOCUMENT v3.22.2
Acquisitions - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Apr. 16, 2021
Sep. 30, 2022
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
Business Acquisition [Line Items]              
Net increase in goodwill         $ 7    
Goodwill     $ 14,865   14,865   $ 14,890
Loss on divestiture         560 $ 0  
Payments to Acquire Businesses, Net of Cash Acquired         0 1,626  
Acquired in-process research and development     0 $ 1,505 0 $ 1,505  
Gensenta Ilac Sanayi vs Ticaret              
Business Acquisition [Line Items]              
Disposal Group, Including Discontinued Operation, Assets     80   80    
Disposal Group, Including Discontinued Operation, Accrued Liabilities     20   20    
Disposal Group, Including Discontinued Operation, Assets, Current     100   100    
Gensenta Ilac Sanayi vs Ticaret | Other Operating Income (Expense)              
Business Acquisition [Line Items]              
Loss on divestiture     560        
Gensenta Ilac Sanayi vs Ticaret | Forecast [Member]              
Business Acquisition [Line Items]              
Proceeds from Divestiture of Businesses and Interests in Affiliates   $ 135          
Teneobio              
Business Acquisition [Line Items]              
Net increase in goodwill         22    
Cash paid         993    
Maximum additional consideration due contingent on certain milestones     1,600   1,600    
Contingent consideration obligation for acquisition         299    
Acquired in-process research and development     991   991    
Deferred tax liability     244   244    
Goodwill     273   273    
Teneobio | R & D Technology rights              
Business Acquisition [Line Items]              
Value of intangible assets acquired         $ 115    
Weighted average period of amortization         10 years    
Teneobio | Licensing rights              
Business Acquisition [Line Items]              
Value of intangible assets acquired         $ 41    
Teneobio | In-process Research and Development | AMG 340              
Business Acquisition [Line Items]              
Acquired in-process research and development     $ 784   $ 784    
Five Prime Therapeutics, Inc.              
Business Acquisition [Line Items]              
Payments to Acquire Businesses, Net of Cash Acquired $ 1,600            
Acquired in-process research and development 1,500            
Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets 177            
Other liabilities $ 47